Lite Strategy (LITS) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lite Strategy (LITS) has outperformed Metagenomi Therapeutics (MGX) over the past year, losing 48.2% versus a loss of 68.9%. Metagenomi Therapeutics is the larger company by market cap ($37.5 million vs $37.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LITS | MGX |
|---|---|---|
| Share price | $1.22 | $0.9932 |
| Market cap | $37.10M | $37.52M |
| 1-day change | -3.94% | +0.86% |
| YTD return | -3.79% | -38.69% |
| 1-year return | -48.16% | -68.87% |
| 5-year return | -97.82% | — |
| EPS (TTM) | $-2.06 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.97 | $3.95 |
| 52-week low | $0.69 | $0.96 |
| Distance from 52-week high | -58.92% | -74.86% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +604.79% |
| Average volume | 462.76K | 158.27K |
| Shares outstanding | 30.41M | 37.78M |
| Employees | 5 | 113 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LITS has outperformed MGX by 20.7 percentage points over the past year.
About Lite Strategy
LITS stock →Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
Healthcare · Biotechnology · 5 employees
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Healthcare · Biotechnology · 113 employees
LITS vs MGX FAQ
Which is bigger, Lite Strategy or Metagenomi Therapeutics?
Metagenomi Therapeutics (MGX) is larger, with a market capitalization of $37.52M compared with $37.10M for Lite Strategy (LITS).
Which stock has performed better over the past year, LITS or MGX?
LITS returned -48.16% over the past 12 months, compared with -68.87% for MGX (price return, excluding dividends). Past performance does not predict future results.
Are Lite Strategy and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.